Protocol CAM307: A Phase 3 Study to Evaluate the Efficacy and Safety of Front-line Therapy with Alemtuzumab (Campath®) vs Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia

Results to be posted pending publication

Drug Name	Generic Name	Therapeutic Area and FDA Approved Indications:	Approved U.S. Drug Label
Campath®	Alemtuzumab	B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy	Prescribing Info NOTE: This product is manufactured by Genzyme Corporation and distributed by Bayer Healthcare Pharmaceuticals